Translate

Friday, April 3, 2020

thumbnail

AVEO AVEO Pharmaceuticals, Inc. gains 16% Apr 3, 2020

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.http://www.priceseries.com/trade/AVEO-AVEO-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020032520200403.html

Thursday, April 2, 2020

thumbnail

ATHX Athersys, Inc. gains 26% Apr 2, 2020

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.http://www.priceseries.com/trade/ATHX-Athersys-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2020032620200402.html

Friday, March 13, 2020

thumbnail

VIRT Virtu Financial, Inc. gains 37% Mar 13, 2020

Virtu Financial, Inc., together with its subsidiaries, provides market making and liquidity services to the financial markets worldwide. The company offers a technology platform through which it provides quotations to buyers and sellers in equities, commodities, currencies, options, fixed income, and other securities on various exchanges, markets, and liquidity pools. Virtu Financial, Inc. was founded in 2008 and is headquartered in New York, New York.http://www.priceseries.com/trade/VIRT-Virtu-Financial-Inc-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2020013020200313.html

TradeVisor Product Review

Review I II III IV

Blog Archive